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Mesoporous silicon is a form of silicon that has nano-sized holes (size 2 - 50 nm) in its structure. It can be 
used as a material for preparing nanoparticles (size less than 100 nm). The particles are non-toxic and have 
advantageous drug carrier properties. The porous surface provides a large surface area for drug delivery 
purposes. The surface can be modified to increase the resistance against degradation of the material. The 
surface chemistry of the particles and the properties of a drug as well as some external factors (for instance 
the composition of release medium) have an impact on both drug loading and release. The drug release 
can be rapid or, more preferably for targeted drug delivery, sustained. Furthermore, some surface 
modifications improve the migration of particles to desired targets including malfunctioning organs, 
inflamed tissues and tumor cells while the others allow the sustaining of the drug release until the particles 
end up in their destination.  
The drug release properties of nanoparticles are often monitored by labeling the cargo and/or the carrier. 
Traditional methods include using radioactive and fluorescent labels. Moreover, non-labelling 
bioluminescence based methods have recently attracted attention due to their simplicity compared to the 
label-based methods. An interesting idea is using D-luciferin as a drug-like model molecule. D-luciferin is 
fluorescent, has drug-like properties and also serves as a substrate in a bioluminescence reaction catalyzed 
by luciferase. 
In this study drug loading and release properties of mesoporous silicon nanoparticles were studied by 
using D-luciferin as a drug-like model molecule. D-luciferin was un-covalently loaded into three types of 
porous silicon particles. Fluorescence measurements were performed in order to compare drug loading 
properties of the particles. The most potent carrier candidate was loaded in order to carry out 
an enzymatic release study. 
The results showed the highest loading capacity for thermally carbonized porous silicon nanoparticles. 
Unfortunately, these particles showed a rapid release of all of the loaded D-luciferin. On the other hand, 
methods used in the current study were realized to be useful for comparing drug release properties of 
different types of porous silicon nanoparticles. The loading and release study could be repeated with the 
same protocol using some other particles. Furthermore, the release medium requires optimization. Strong 
bioluminescence light provides prospects to use D-luciferin as a model drug/label for imaging drug delivery 
with luciferase transfected cells. 
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ABBREVIATIONS 
 
% w/w Drug loading degree (mdrug loaded / (mdrug loaded + mparticle) 
AEAPMS 3-(2-aminoethylamino) propyldimethoxymethylsilane 
AMP Adenosine monophosphate 
BSA Bovine serum albumin fraction V 
Chloramine T Tosylchloramide sodium 
CPP Cell penetrating peptide 
D-LH2 D-luciferin 
DLS Dynamic light scattering 
DMSO Dimethylsulfoxide 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
FLIC Luciferase-specific inhibitor compounds 
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FLuc Firefly luciferase 
FTIR Fourier transform infrared spectroscopy 
HPLC High pressure liquid chromatography 
IODO-GEN 1,3,4,6-tetrachloro-3α,6α-diphenyl glycoluril 
LBL Layer-by-layer self-assembly 
MCM-41 Mobil Composition of Matter 41 
MPS Mononuclear phagocyte system 
O-PEG Oleyl-poly(ethylene glycol) 
PBS Phosphate buffer saline 
PEG Poly(ethylene glycol) 
pKa logP (log (coctanol / c water) 
PPi Pyrophoshpate 
PSi Porous silicon 
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RO5 Lipinski’s rule of five 
SSA Specific surface area 
TCPSi-NH2 Amine treated thermally carbonized porous silicon particles 
TEM Transmission electron microscopy 
TG Thermogravimetry 
UnTHCPSi Undecylenic acid treated thermally hydrocarbonized porous silicon 
WOPSi-NH2 Amine treated wet-oxidized porous silicon particles 
XRD X-ray diffraction 
ζ-potential Zeta potential 
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Introduction 
Nanomedicine is a multidisciplinary field of research where the interest is in using nanomaterials 
to the advancement of health. One area of nanomedicine is targeted drug delivery where the goal 
is to deliver medications to the diseased area of the body in a manner that accumulates the drug 
to that area. The material is processed to different sizes of particles to carry drug molecules. For 
targeted drug delivery the type of particles are called nanoparticles. Nanoparticles are often 
defined as particles with a diameter less than 100 nm in diameter (Royal Society, 2007). The 
surface of the nanoparticles is modified to increase the circulation time in the body, cell specific 
targeting and membrane permeability. The properties of nanoparticles for example in cells 
(Bimbo et al. 2010) and in the body (Rytkönen et al. 2012) can be studied by labelling the particles 
with a radioactive or fluorescent label. Alternatively, the labelling of the cargo enables to study 
the release of the cargo. 
D-luciferin ((S)-2-(6-hydroxybenzothiazol-2-yl)-2-thiazoline-4-carboxylic acid; PubMed ID 
24896524) is a potential alternative marker for nanoparticle research. D-luciferin (D-LH2) is an 
optical stereoisomer of luciferin (LH2) whose asymmetric atom is carbon 2 in the thiazoline-
carboxylic acid moiety (Marques & Esteves da Silva, 2009, Seliger et al. 1961) (Fig. 1). With 
magnesium ion (Mg2+) and adenosine-triphosphate (ATP) D-LH2 serves as a substrate to firefly 
luciferase (FLuc) in a bioluminescence reaction resulting in emission of visible light. (Seliger et al. 
1961) (Fig. 1) 
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Figure 1. The luminescence reaction of D-luciferin (MW 280.32 g/mol) is a multistep process catalyzed by 
luciferase. The asymmetric carbon (circled) may change the structure to L-stereoisomer which does not 
react to emit yellow-green light. (1) In the first step, adenosine triphosphate (ATP) reacts with the 
carboxylic group of the thiazoline-carboxylic acid moiety of D-luciferin (D-LH2). The hydrolysis of ATP 
produces pyrophosphate (PPi) and D-luciferyl-adenylate (LH2-AMP), which may be induced by a bivalent 
cation (not shown). (2) In the second step molecular oxygen (O2) replaces AMP forming dioxetanone. (3) 
Finally, carbon dioxide (CO2) binds resulting oxyluciferin with an excited electron. Visible light (hν) is 
emitted for releasing the excitation state. (Modified from Marques & Esteves da Silva, 2009, Thorne et al. 
2010) 
The structure of D-LH2 abides well the common drug-like properties (Lipinski et al. 1997, Lipinski, 
2004) (Fig. 1). The size of D-LH2 is small and it can be used as a model drug for nanoparticle loading 
and the release studies in FLuc containing environment. Traditionally, FLuc transfected cells are 
widely used in reporter gene assays are for imaging purposes (McElroy, 1951). The most notable 
advantage in using D-LH2 as a model drug is to avoid the need for additional labeling which may 
affect the release of the cargo from nanoparticles as well as standard biological functions of cells. 
With this method one may also run a dual experiment to study both the release kinetics of D-LH2 
from nanoparticles and the transportation of traditionally labeled nanoparticles separately.  
There are few publications dealing with combining D-LH2 with porous silicon nanoparticles. For 
instance, Ding et al. (2012) introduced a method to study the effect of different nanoparticles to 
the Fluc transfected cells by loading D-LH2 to the particles. Sun et al. (2011) showed mesoporous 
silicon nanoparticles can be used as a co-delivery system for enzymes and substrates in order to 
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control intracellular catalytic reactions. However, those studies do not focus on using D-LH2 as a 
drug-like molecule for porous silicon mediated drug delivery.  
In this report D-LH2 was used as a model drug in order to test suitability of different porous silicon 
nanoparticles for drug loading and release for targeted drug delivery applications. In the first 
paragraph, porous silicon is introduced from the point of manufacturing and surface 
modifications. Furthermore, the principles of loading and release of small drugs using different 
types of porous silicon nanoparticles are discussed ending up comparison of the structural 
properties of D-LH2 with recently loaded drug molecules (antipyrine, ibuprofen, griseofulvin, 
furosemide, ranitidine and indomethacin). In the end of the review some traditional radioactive 
and fluorescent labelling methods for nanoparticle research are introduced. Finally, in the 
experimental section D-LH2 was loaded to three porous silicon nanoparticles with varying surface 
chemistries. The loading efficiency and the loading degree were determined by fluorescent 
spectroscopy. The release kinetics was studied using FLuc recombinant and measuring the 
luminescence light. 
1. Literary review 
2.1. The history of porous silicon - from optoelectronics to nanomedicine 
Porous silicon (PSi) was accidentally manufactured during electropolishing of semiconductors for 
electronics industry in the 1950s (Uhlir, 1956). Instead of smooth corrosion the experiment 
resulted in the formation of pores on the surface of the substrate. The finding did not wake 
a remarkable interest until 1990 when prof. Canham reported the visible light emission after 
exciting PSi at room temperature by an external source of light. The discovery attracted attention 
in the optoelectronic industry (Torres-Costa et al. 2010) and also paved the way for the later 
progress of label-free imaging with luminescent nanoparticles (Park et al. 2009). 
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The crucial turning point in using PSi in medical applications took place when the pores of PSi 
were demonstrated to be linked to its bioactivity (Canham, 1996). In simulated body fluid PSi was 
shown to induce the growth of artificial hydroxyapatite, which, surprisingly, was dependent on 
the pores on the surface of PSi (Canham, 1996). The study not only inspired researchers to 
synthetize more functional PSi-based biomaterials for bone injuries (Canham, 2000, Low et al. 
2006, Low et al. 2010) but also initiated engineering the material for other applications, for 
example PSi-based biosensors (Dhanekar & Jain, 2013, Mathew & Alocilja, 2003).  
Some studies revealed that PSi could also be used as a safe material for drug delivery purposes. 
In 1998 Popplewell et al. carried out a study where silicon 32-isotope was administrated orally to 
a human subject. Mass spectroscopy measurements showed 90 % of the total gastrointestinal 
absorpted silicon was rapidly eliminated to non-toxic soluble orthosilic acid with a half-time of 
2.7 hours. On the other hand, Anderson et al. (2003) showed the solubility in physiological 
conditions could be controlled by changing the porosity of a PSi layer.  
Later many studies have presented methods how to increase the stability of PSi in the 
physiological conditions by modifying the surface chemistry of PSi. One of the very first positive 
demonstrations was carried out by Canham et al. (1999). In the study the stability of PSi layer in 
human blood plasma was dramatically increased after the surface of the silicon wafer was 
derivatized with 1-dodecyne. Several other studies have followed by variety of new stabilization 
methods against both oxidation and immunological responses from simple oxidation and 
carbonization methods (Bimbo et al. 2010, Limnell et al. 2007, Salonen et al. 2004, Wang et al. 
2010) to complex linking of polymers (He et al. 2011, Passirani et al. 1998). 
In 1992 a study by Mobil Corporation launched a technology to industrial catalytic purposes which 
could be used for receiving ordered silica sieves with hexagonal arrays of identical pores. One of 
their developed sieve type is called as MCM-41 (Mobil Composition of Matter). The size of pores 
of MCM-41 varies between 2 and 50 nm defining a mesoporous material (Rouquerol et al. 1994). 
MCM-41 attracted attention as a potential platform for loading and sustaining the release of 
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poorly soluble drug molecules. In consequence, ibuprofen was the first model anti-inflammatory 
drug to be loaded into the pores of a MCM-41 wafer showing prolonged release in simulated body 
fluid (Vallet-Regi et al. 2001). The study gave evidence that morphologically similar silica pores 
can be used as ordered drug storing “pockets” without irreversible structural changes in the drug. 
Later some in vitro studies showed the loading and release properties are unavoidably dependent 
the physico-chemical properties of both a drug and the nanoparticles (Limnell et al. 2007, Salonen 
et al. 2005) indicating a requirement to perform separate loading and release tests for each drug 
carrier system. 
Apart from taking advantage of nanoparticles as pharmacokinetic regulators there has been 
increased interest to use nanoparticles in targeting delivery of drugs to specific cells and tissues. 
Targeting would advance treatment of many obstinate diseases for example cancer therapy with 
cytostatic since most cytostatics are cytotoxic also for normal cells. Cytotoxicity for normal body 
cells may cause serious effects for example in the heart (Piasek et al. 2009). In fact, some 
interesting studies have recently come up regarding utilizing different biomolecules with specific 
cell transportation activities to increase the cell membrane permeability for several drug delivery 
systems (Hu et al. 2013, Kinnari et al. 2013, Park et al. 2005, Park et al. 2013). One example of 
those kind of biomolecules are cell-penetrating peptides (CPPs) which serve as ligands for 
endocytosis-inducing receptors expressed on the cell membrane (Arukuusk et al. 2013, Heitz et 
al. 2009, Mäe et al. 2009, Oskolkov et al. 2011). The first studies of combining CPPs with PSi 
nanoparticles have already been performed with promising results of improving tumor homing 
and even cell organelle specificity (Kinnari et al. 2013). The properties and applications of CPPs 
are described with more details elsewhere in the literature. Instead, in the current review we 
focus on the preparation and basic surface modification of non-specific delivery of PSi 
nanoparticles followed by discussion about what factors do actually affect the drug loading and 
release of small pharmaceuticals. Furthermore, different labelling methods for drug delivery are 
discussed. 
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2.2. Manufacturing and characterization 
2.2.1. Classification of manufacturing methods of porous nanomaterials 
Techniques for manufacturing of different types of porous nanomaterials can be divided to two 
main classes called bottom-up and top-down technologies which are based on contrary principles 
(Fig. 2). Bottom-up is based on using molecules and atoms as “building blocks” which are physico-
chemically self-organized together to form a porous structure while top-down comprises 
reduction of a bulk material to nanoscale objects. (Raab et al. 2011) Bottom-up manufacturing 
techniques include an abundance of methods which can be further subcategorized into liquid 
phase and gas phase processes (Hofmeister et al. 1998, Li et al. 2004, Trewyn et al. 2007). The 
processes encompass for instance sol-gel (Trewyn et al. 2007), laser (Li et al. 2004), thermal and 
plasma-assisted processes (Hofmeister et al. 1998). 
 
Figure 2. Two main technologies to produce porous nanomaterials differ from their starting point.  The 
initial step of top-down techniques comprises for example a milling of a macro-sized material while 
bottom-up processes utilize the interactions between atoms and molecules. (Raab et al. 2011) 
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For drug delivery applications PSi nanoparticles are manufactured with top-down technology. The 
method is based on the original invention of Uhlir (1956). Briefly said, pores are directly etched 
to a solid layer in hydrofluoric acid solution (HF) either chemically with a strong oxidizing agent 
(for instance nitric acid) (Li et al. 2004, Vazsonyi et al. 2001) or electrochemically using an external 
electric field (Nychyporuk et al. 2006, Sailor, 2012, Salonen & Lehto, 2008, Trucks et al. 1990). 
Although some studies prefer to use oxidation techniques, electrochemical etching seems to 
stand the test of time as the most used method.  
2.2.2. Electrochemical fabrication of porous silicon nanoparticles 
Electrochemical etching can be performed with several types of equipment. The simplest system 
involves dipping two plates into the fabrication cell with a HF -solution (Fig. 3). The first plate is 
made of silicon and the other one is often platinum. The fabrication cell must be HF-resistance 
material, for instance Teflon. Switching the power supply on the etching begins as half reactions 
resulting etching of the silicon layer. (Salonen et al. 2008) One end product is hydrogen gas. 
Ethanol is added to improve the release of hydrogen bubbles from the pores and the external 
surface of the material. (Bley et al. 1996, Salonen et al. 2008) 
 
Figure 3. A comprehensive system for porous silicon etching. In the etching process the silicon layer is 
porosified whilst on the surface of non-corrosive platinum hydrogen is released. (Salonen, 2013) 
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For drug delivery, it is essential to achieve a high degree of pore homogeneity. The similarity of 
the pores is dependent on several parameters which may also be dependent on each other. These 
are for example an etching current (Asma et al. 2009, Nychyporuk et al. 2006), etching time, the 
composition of the electrolyte, (Bley et al. 1996) and even the presence of light (Kovalev, 2004). 
In addition, the type (phosphorus, n-type or boron, p-type) (Smith & Collins, 1990) and a 
proportion of the dopant (Yaakob et al. 2012) in the bulk silicon are extremely important factors 
affecting the success of the etching. A dopant gives a desired resistance to the pure silicon. The 
success of the etching can be seen in transmission electron microscopy (TEM) pictures (Smith & 
Collins, 1990) (Fig. 4). The etching mechanisms are complicated involving multiple breakings and 
formations of covalent bonds (Si-H, Si-F, Si-O, Si-Si) and are discussed carefully elsewhere (Sailor, 
2012, Trucks et al. 1990). 
 
Figure 4. Cross-sectional transmission electron microscopy pictures of the porous silicon morphologies 
after anodizing in 10 % hydrofluoric acid at the current density 10 mA/cm2. a) n-type porous silicon. b) p-
type porous silicon. (Smith & Collins, 1990) 
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2.2.3. Drying and fragmentation of porous silicon films 
Mechanical fragmentation of the etched PSi films is crucial in order to achieve a nanopowder 
appearance for PSi material. The fragmentation is usually carried out by ultrasonic dispersion 
(Bley et al. 1996, Kale, 2010, Park et al. 2009) or ball-milling (Bimbo et al. 2010, De Castro & 
Mitchell, 2002, Heintz et al. 2008, Kovalainen et al. 2012, Russo et al. 2012). An ethanol-based 
medium decreases the surface tension preventing the evaporation of the liquid from the pores 
(Björkqvist et al. 2003). The size distribution of the particles is studied by using a dynamic light 
scattering (DLS) or TEM instrument. (Bimbo et al. 2010, Rytkönen et al. 2012) 
The fragmentation technique needs to be chosen according to the application where the particles 
are utilized. Ultrasonication is based on using high-frequency sound waves (> 20 kHz) to agitate a 
liquid sample (Royal Society of Chemistry 2013). It is effective especially for producing mono-
dispersed luminescent nanoparticles (2 - 10 nm in diameter) for optical devices (Bley et al. 1996, 
Kale, 2010) and label-free imaging applications (Park et al. 2009). Instead, milling with ceramic 
balls is more used for producing drug carriers (Bimbo et al. 2010, Kovalainen et al. 2012, Rytkönen 
et al. 2012, Salonen et al. 2005). Milling results a wide particle-size range (Raab et al. 2011) but 
an extremely accurate particle size is required mainly in studies dealing with luminescence 
properties of nanoparticles.  
Although fragmentation is a simple step in the nanoparticle fabrication, it still requires 
optimization. The size of particles and their pore morphology are not only important factors for 
determining the surface area for drug loading (Limnell et al. 2007) but have also other effects. For 
instance, cellular internalization (Huang & Chen, 2011) and in vivo biodistribution are dependent 
on the outer appearance of the PSi particles (He et al. 2011).  
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2.2.4. Stabilization against oxidative and chemical decomposition 
It is well known that PSi is instabiel in ambient conditions and used to oxidize spontaneously over 
time. The reason is the oxidation of silicon hydrides (Si-Hx) on the PSi surface. (Canham et al. 1991, 
James et al. 2006) The oxidation has severe consequences. Firstly, the oxidized silicon particles 
have been noticed to degrade easily in a basic water solution, which sets boundaries to the 
utilization of PSi particles in drug delivery applications (Björkqvist et al. 2003). Secondly, the 
oxidation of PSi increases remarkably the hydrophilic nature of the PSi surface having an influence 
on the loading and the release of the cargo (Limnell et al. 2007). In the worst case, unnoticeable 
changes in the surface chemistry affect the reliability of results from experiments performed with 
differently aged PSi samples (Björkqvist et al. 2003, Salonen et al. 2005). 
There are various stabilization methods including surface oxidation (Salonen et al. 2005, Salonen 
et al. 2008, Wang et al. 2010) and hydrocarbonization methods (Fig. 5) (Bimbo et al. 2010, Heintz 
et al. 2008, Kovalainen et al. 2012, Salonen et al. 2005, Salonen et al. 2008, Xia et al. 2005). Some 
studies propose more uncommon techniques for example rapid-thermal-oxidation of PSi layer 
performed after the etching process (Petrova-Koch et al. 1992). However, the immediate post-
stabilization after the milling step is more common. The success of the stabilization can be studied 
by analyzing the spectra received from Fourier transform infrared spectroscopy (FTIR) (Chen et al. 
1996, Limnell et al. 2007, Salonen et al. 2004, Xia et al. 2005) or measuring the weight increase in 
the particles (Salonen et al. 2004). The effect of the stabilization to the pore size should also be 
considered when designing a stable platform for a drug delivery application (Salonen et al. 2005).  
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Figure 5. Porous silicon nanoparticles can be stabilized either by surface oxidation (left) or carboxylation 
(right). x = 1, 2, 3 (Modified from Kovalainen et al. 2012) 
Stabilization by surface oxidation consists of generation of multiple Si-O bonds which protect from 
lytic oxidation. The stabilization is carried out at a high temperature either in the exposure of pure 
oxygen gas (Aggarwal et al. 2013) or in ambient air (Björkqvist et al. 2003, Kovalainen et al. 2012). 
Pure oxygen gas has been shown to form a stable protection lasting longer than PSi treated with 
ambient air (Aggarwal et al. 2013). Despite of that, using ambient air seems to be more common 
for its easy availability (Björkqvist et al. 2003, Kovalainen et al. 2012). Using high temperature is 
avoidable by performing the reaction at milder temperature for a longer time (Kovalainen et al. 
2012) or humidifying the hot air when piped into the reactor (Chen et al. 1996). In fact, some 
studies have estimated that using a wet oxidation temperature of 400 - 500 °C has an equal 
oxidation rate than that of the dry oxidation method performed at 800 or 900 °C (Chen et al. 
1996). Nevertheless, using dry ambient reaction conditions appears to be a more general 
procedure since the stabilized sample can be taken immediately to further experiments without 
using an additional drying equipment. 
An unfortunate disadvantage of using oxidation is the instability of the oxidized PSi in the 
presence of bases. It has been experimentally demonstrated that oxidized PSi is soluble in 
a potassium hydroxide solution (Björkqvist et al. 2003). Fortunately, hydrocarbonized PSi surface 
has shown to be a potent alternative stabilization method to improve both oxidation and 
chemical stability (Björkqvist et al. 2003 Salonen et al. 2004). Contrary to oxidation techniques, 
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hydrocarbonization requires an additional HF/ethanol-treatment for PSi sample in order to 
replace the oxide layer on the PSi surface with hydrogen atoms. After that PSi nanoparticles are 
treated with a continuous flow of nitrogen and acetylene mixture. Heat energy is being employed 
to activate the covalent replacement of the surface-bound hydrogen atoms with carbon atoms. 
(Salonen et al 2004)  The formed layer is highly hydrophobic showing to be a good carrier of 
hydrophobic drugs. The hydrophilicity can be increased by annealing the sample above 680 °C. 
(Salonen et al. 2005) The hydrophilicity is studied by analyzing the humid sorption properties of 
the cooled sample (Salonen et al. 2004). 
Hydrosilylation is another stabilization method. It utilizes some chemicals as an initiator for the 
stabilization reaction performed in a liquid phase (Buriak et al. 1999, Xia et al. 2005). Some 
examples of these methods include Lewis base treatment (e.g. ethylene aluminum dichloride) of 
alkenes and alkenyls (Buriak et al. 1999) or the formation of a more compact polymer network 
around the surface of PSi (for instance polydimethylsiloxane) (Xia et al. 2005). 
2.2.5. Surface modification for in vivo applications 
Intravenous administration of therapeutic substances has proved to be the simplest strategy for 
drug delivery. However, a notable disadvantage of using blood circulation as a drug transportation 
route is that particles are rapidly removed by the mononuclear phagocyte system (MPS) (Owens 
& Peppas, 2006). Macrophages are one of the most characterized cell types of MPS which prevent 
effective drug delivery (Frank & Fries, 1991, Owens & Peppas, 2006). Macrophages indirectly 
recognize particulates via plasma proteins called opsonins which bind to the surface of 
particulates (Frank & Fries, 1991). The process ends up in the fast clearance of the particulates 
into liver and spleen as well as to the urinary excretion reducing the bioavailability of a 
delivered drug (He et al. 2011, Park et al. 2009).  
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Several studies focus on the chemical modification of PSi surface to prevent the binding of 
opsonins. Some interesting approaches have already been reported such as covering the surface 
with proteins (Sarparanta et al. 2012) and carbohydrates (Passirani et al. 1998). In spite of the 
natural origin of those molecules stabilization with a synthetic but still non-toxic polymer called 
poly(ethylene glycol) (PEG) has awoken high interests among researchers (He et al. 2011, Owens 
& Peppas, 2006, Park et al. 2009, Rytkönen et al. 2012, Suh et al. 2007). Although PEG has been 
shown to reduce the opsonization of PSi in vitro the problem with short circulation time in vivo 
has not yet been solved. (Rytkönen et al. 2012) 
PEGylation is adding PEG chains to a material. PEG can be synthetized as different derivates 
depending on the type of preliminary chemistry of the PSi surface. Hydrocarbonized particles can 
be simply PEGylated with hydrophobic forces between the long unsaturated hydrocarbon of 
oleyl-PEG and the hydrophobic surface of THCPSi (O-PEG) (Fig. 6a). On the other hand, the 
covalent-conjugation to the hydrocarbon surface has been performed by using O-PEG with an 
additional methyl group. The methyl is chemically removed for example with acetonitrile in order 
to enable binding of PEG to the surface. (Rytkönen et al. 2012) The outer tail of the PEG chain 
provides variety options for functionalization (Owens & Peppas, 2006) although some non-PEG 
carboxyl and amino linkers have also shown to be effective for covalent conjugations (Mäkilä et 
al. 2012, Schwartz et al. 2005, Xu et al. 2012). The concentration of PEG and the length of the 
polymer must be optimized in order to achieve a long-lasting “brush-like” shield (Fig. 6b, c).  
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Figure 6. a) The structures of poly(ethylene glycol) (PEG) (left top corner) and its general derivate 
compounds. The coverage of PEG compounds can be seen in represented three dimensional schematic 
pictures. b) In the low coverage the PEG chains are located near the particle surface. c) In the high coverage 
PEG chains forms a brush-like appearance, which leads to a steric barrier for opsonization (Modified from 
Owens & Peppas, 2006).  
PEGylation changes the structural parameters of the particles. First of all, PEGylation may alter 
the particle surface charge also known as zeta potential (ζ-potential). Furthermore, a PEG layer 
gives a new size to the particles called hydrodynamic size. (Rytkönen et al. 2012) Changes in these 
two parameters may affect the function of a drug delivery system. For example, Suh et al. (2007) 
reported that PEGylation of polymeric nanoparticles show clear transportation in HeLa cell line 
decreasing the portion of the hindered transportation mechanisms by 30 %. Both ζ-potential and 
hydrodynamic size can be measured with a DLS instrument (Rytkönen et al. 2012). 
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2.3. Porous silicon nanoparticles in targeted drug delivery applications 
2.3.1. Strategies to prolong the release of drugs 
PSi particles have turned out to be a versatile tool for targeted delivery of small pharmaceuticals. 
The drugs are loaded inside the pores of PSi particles where they are stabilized against negative 
effects of various environmental conditions (Salonen et al. 2005, Sarparanta et al. 2012). The 
simplest loading procedure is based on the hydrophobic interactions between the drug and 
particle surface. The PSi particles and drugs are simply mixed together in a solvent and incubated 
for an appropriate time. (Kovalainen et al. 2012, Limnell et al. 2007, Salonen et al. 2005) A 
pressure caused by ultrasonicating can be used for speeding up the loading (Kovalainen et al. 
2012). The loading solvent is chosen according to the solubility of the drug and is in most cases 
water, ethanol or dimethylsulfoxide solutions (DMSO) (Kovalainen et al. 2012, Limnell et al. 2007, 
Salonen et al. 2005). The function of the solvent is to drive drug molecules into the pores. The 
release is tested in a different solvent where the drug diffuses out of the pores. The amount of 
diffused drug can be determined for example by taking a sample from the supernatant for high 
pressure liquid chromatography (HPLC) measurements. (Salonen et al. 2005)  
The solvent is eliminated from the pores by evaporating the solvent from the loaded particles. 
During the evaporation the drug either crystallizes inside the pores having either a poorly water-
soluble perfect crystal lattice or easily-soluble amorphous appearance. (Limnell et al. 2007, 
Salonen et al. 2005, Wang et al. 2010) For example indomethacin exists in both the poorly water-
soluble γ-form and more soluble α-form distinguishing with their melting points (Hancock & 
Parks, 2000).  
Although it is complex to control the transition between a crystal and an amorphous form some 
parameters have already been found. Salonen et al. (2005) showed the phenomenon is 
dependent on the original solubility of the drug (Fig. 11) while Limnell et al. (2007) reported the 
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size of the confined space of pores plays also a crucial role. The release experiments of those 
studies were performed in a buffered salt solution with fixed pH in order to simulate the stability 
of the delivery system in the different stages of the oral administration route. For targeted drug 
delivery it is extremely important to always test the release with other simulating mediums, 
especially in plasma (Tay et al. 2004) in order to get a wider insight of the drug release in the 
complex intravenous environment.  
 
Figure 7. Aqueous dissolution profiles of a) loaded soluble antipyrine and b) loaded liphophilic ibuprofen 
from similar size thermally hydrocarbonized porous silicon microparticles with their un-loaded controls 
(solid and open symbols, respectively) in Hank’s balanced salt solution at pH 7.4, +37 °C (n = 3, mean ± sd). 
(Modified from Salonen et al. 2005) 
Reduction of the drug release outside the target tissue, whether it is due to the crystallization 
process or for in vivo factors, is an important goal in the targeted drug delivery applications. 
Instead of being totally eliminated the release usually follows a zero-order trend (Fig. 8). In 
targeted delivery, premature drug release has been found to have many negative effects for 
example uneconomical drug consumption, reduced therapeutic effects in the target as well as 
toxicity in healthy tissues. Sometimes the initial release is unpredictably rapid occurring within a 
short time period. The phenomenon is called burst effect and its origin is not fully understood. 
(Huang & Brazel, 2001) (Fig. 8) 
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Figure 8. A schematic diagram of the burst effect in a zero - order drug delivery system. (Huang & Brazel, 
2001) 
Efforts have been done to achieve a controlled release system for targeted drug delivery 
applications (Huang & Brazel, 2001). Functionalization of the internal surfaces of PSi particles 
allows drugs to be loaded and trapped by covalently capping the openings of the pores. This 
technique allows the external surface to stay untouched for other useful modifications. After 
transportation to a cell the drug release is triggered for instance by enzymatic stimuli (Fig. 9). (Lai 
et al. 2003) However, it has been noticed that it is challenging to add functional groups selectively 
into the internal space of the etched particulates (Trewyn et al. 2007).  
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Figure 9. A schematic example of prevent the escape of drugs from the pores by sulfide-functionalized 
cadmium nanoparticles (CdS) in vitro. The cleavage of the disulfide-bridges is trigger by a dithiothreitol 
(DTT) reducing agent. (Lai et al. 2003) 
Another interesting method for coating and crosslinking of polymeric material includes cellular 
stimuli responsive polyelectrolytes (De Villiers et al. 2011). For example chitosan and dextran 
sulfate are used (Yuan et al. 2010). The subunits are adsorbed to the surface of particles as 
positively and negatively charged monolayers, which results a multilayer coating. This method 
called layer-by-layer self-assembly (LBL) and it has been used for inhibiting dissolution of 
microcrystal drugs (Shenoy et al. 2004, Qiu et al. 2001). Furthermore, some LBL produced 
nanocoatings have other advantages (De Villiers et al. 2011). For instance, an increase in the 
antibacterial property of silver nanoparticles has been reported (Yuan et al. 2010). 
2.3.2. The concepts and characterization of drug loading and release 
Several concepts have been created to express the drug loading results. One is the specific surface 
area (SSA) which consists of the total surface area per unit of the particle mass. The higher the 
amount of pores the larger is the value of the SSA. A wider SSA increases the likelihood of drugs 
to interact with the surface of a carrier. On the other hand, the small volume of pores means the 
fact that only few drugs are capable to fit into the narrow internal space of the small nano-pores. 
(Limnell et al. 2007) 
The amount of the loaded drug is generally expressed as loading degree using the dry weight of 
both the loaded drug and particles (Eq. 1) Un-covalent drug loading prefer to end up a heterogenic 
equilibrium between the loaded and un-loaded drug (Salonen et al. 2005). 
Loading degree = mdrug loaded / (mdrug loaded + mparticle) × 100 % w/w   (Eq. 1)  
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The calculated value of % w/w varies significantly not only for physico-chemical properties but 
also used analytic method. For instance, Salonen et al. (2005) reported the computational N2 
sorption technique to yield erroneous results due to the blockage of pores by drugs. In order to 
increase the reliability of measured results of quantity and the state (2.4.1.) of a drug inside the 
pores, different characterization methods such as XRD and HPLC should be used simultaneously 
(Kovalainen et al. 2012, Limnell et al. 2007, Salonen et al. 2005, Wang et al. 2010) 
2.3.3. Model drugs 
In drug delivery studies, model drugs are used to give insight in which particle type is the most 
suitable one for drug carrier functions. A compound is accepted for drug delivery studies if it 
shows drug-likeness. Drug-likeness is determined according to Lipinski’s rule of five (RO5) named 
by its developer in 1997 (Lipinski et al. 1997). Originally, the conditions of RO5 were settled down 
for improving screening of orally bioavailable substances from the abundance of compounds with 
varied physicochemical properties cumulated from numerous combinatorial and medicinal 
studies. RO5 is based on the observation that oral bioavailability, the condition for the 
achievement of the phase II clinical status, is associated with molecular size (molecular weight ≤ 
500), the partition efficient logP (log (coctanol / c water) ≤ 5) and also the number of hydrogen bond 
donors and acceptors (≤ 5 and ≤ 10, respectively). (Lipinski, 2004, Lipinski et al. 1997) 
During the last decade drugs with different pharmacological functions are widely used as a model 
drug for PSi drug delivery studies (Limnell et al. 2007, Salonen et al. 2005, Vallet-Regi et al. 2001, 
Wang et al. 2010) (Fig. 10. compounds 1 - 6). D-LH2 passes also all of the RO5 conditions (Fig. 10. 
compound 7). The major biological function of D-LH2 is to serve as a substrate for the 
bioluminescence reaction catalyzed by FLuc (White et al. 1969) although some recent studies 
have shown it to have pharmacologically interesting functions (Hu et al. 2012). 
30 
 
 
 
Figure 10. The structures of model drugs (1 - 6) and other drug-like compounds (7) found in research 
publications. (Modified from Salonen et al. 2005)  
2.3.4. Labels for drug delivery studies 
The properties of a drug delivery system can be studied by labeling the particles. Furthermore, 
some labeling methods enable to study the loading and release of a cargo if label-free methods 
cannot be utilized. For instance, labelling may be preferred if a drug have too weak fluorescence 
properties for spectroscopic measurements.  
There are several different labels for nanoparticle research. Radioactive labels, such as iodine 125 
isotope, are used for systemic biodistribution (Rytkönen et al. 2012) and cellular internalization 
studies (Bimbo et al. 2010). Radioactive labels are remarkable useful for labeling aromatic cargos 
without changes in the structure-related properties (Rytkönen et al. 2012). For instance, iodine 
125 has been added into the structure of indomethacin (El-Ghany et al. 2005) and tyrosine 
(Rytkönen et al. 2012) with a simple substitution mechanism of a single atom. Iodine 125 requires 
oxidation of 125I- to 125I+, which can be done for example with IODO-GEN (1,3,4,6-tetrachloro-
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3α,6α-diphenyl glycoluril) (Rytkönen et al. 2012) or chloramine T (tosylchloramide sodium) (El-
Ghany et al. 2005).  
 
Figure 11. IODO-GEN and chloramine T can be used for labeling of aromatic structures with radioactive 
iodine 125 isotope. At first, iodine 125 can be oxidized either by (1) IODO-GEN or (2) chloramine T. (3) 
Then the oxidized iodine is added into a benzene ring. The result depends on the other atoms bound in 
the structure. In this example R1 is the determinant. (Modified from Pubchem Compound, 2014) 
On the other hand, the high energy of the radiation causes a safety risk which must be taken 
account by a researcher (Gjøen & Berg, 2001). Moreover, the radiation of a radioactive label 
cannot give detailed information about the intracellular location of the label. This means, one 
cannot truly tell whether the labeled object is in the nucleus, the cytoplasm or trapped by 
endosomal system leading to degradation (Varkouhi et al. 2011).  
For intracellular imaging of nanoparticles fluorescent labels are widely used. One example is a 
fluorescent compound called fluorescein isothiocyanate (Bimbo et al. 2010) (PubChem ID 18730). 
Fluorescent labels are more used for labeling particles than pharmaceuticals because they are 
likely to change the structure-related properties of a drug. The cellular localization of the labelled 
particles is studied by confocal microscopy (Piepenhagen et al. 2010) but the label must be excited 
by an external source of radiation before it is capable of emitting light. Unfortunately, cells are 
susceptible to phototoxicity. In phototoxicity multiple excitations of a fluorescent label generates 
32 
 
 
singlet oxygen and other reactive oxygen species (Hoebe et al. 2008). The products cause cellular 
stress having many consequences, for example apoptosis.  
3.  Experimental section 
3.1. The purpose of the study 
Mesoporous silicon nanoparticles have been proved to be an effective material for drug delivery 
applications. The aim of this Master’s thesis was to study drug loading and release properties of 
different mesoporous silicon nanoparticles using D-luciferin as a drug like model molecule. Three 
types of porous silicon nanoparticles were used (UnTHCPSi, TCPSi-NH2 and WOPSi-NH2). The study 
begins with a preliminary screening of porous silicon nanoparticles continuing to the optimization 
of the particle concentration and ending up to a simple bioluminescence in vitro release study. In 
the release study D-luciferin serves as a substrate in the light producing bioluminescence reaction 
catalyzed by luciferase. Loading capacity was determined with fluorescence measurements while 
the release kinetics was determined using a luciferase-rich release buffer and a luminometer 
instrument. 
3.2. Materials and methods 
3.2.1. General information of the nanoparticles 
In the current study three amino or carboxyl terminated PSi nanoparticles (UnTHCPSi, TCPSi-NH2 
and WOPSi-NH2) were used. The surface groups allows covalent functionalization for instance 
with peptides (Mäkilä et al. 2012). All the particles had an average particle size between 170 and 
180 nm while pore diameter was around 10 nm. The batches were stored in 99.5 % ethanol (ACS 
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Reagent, Thermo Fischer Scientific, Helsinki, Finland) at -20 °C and were sonicated for couple of 
seconds before use (Branson Ultrasonicator, Danbury, USA). 
3.2.2. TCPSi-NH2 and WOPSi-NH2 particles (amino particles) 
In this study two types of amino modified porous silicon nanoparticles were used. TCPSi-NH2-
particles are thermally carbonized nanoparticles covered with primary amino groups (Fig. 12). 
WOPSi-NH2-particles are wet-oxidized porous silicon amino nanoparticles which differ from the 
latter with the oxidized surface. Both amino particles were manufactured with a silane coupling 
method. The stepwise fabrication procedure includes oxidation of the carbonized/oxidized 
surface with ammonium hydroxide and hydrochloric acid and further treatment with 3-(2-
aminoethylamino) propyldimethoxymethylsilane (AEAPMS) (Xu et al. 2012). Both batches were 
received from the Department of Applied Physics in the University of Eastern Finland (Ph.D. 
Wujun Xu). The age of the TCPSi-NH2 batch was 5 months while the WOPSi-NH2 particles were 
one year old. The zeta potential (ζ-potential) of the particles was +60 mV (Xu et al. 2012).   
 
Figure 12. The surface structure of TCPSi-NH2 and WOPSi-NH2 particles (R1 = Cx and CH2CH2NH2).  
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3.2.3. UnTHCPSi particles (carboxylated particles) 
UnTHCPSi particles were used in order to have a point of contrary to the amino particles. 
UnTHCPSi particles are thermally hydrocarbonized porous silicon nanoparticles with covalently 
attached 1-undecylenic acid chains on outer surface (Fig. 13). The UnTHCPSi-particles were 
manufactured by doctoral student Martti Kaasalainen in the Department of Physics and 
Astronomy in the University of Turku. (Kaasalainen et al. 2012, Kovalainen et al. 2012) The same 
particle batch was used in other studies (Rytkönen et al. 2012). The ζ-potential was around -40 
mV.  
 
Figure 13. The surface structure of UnTHCPSi particles. 
3.2.4. Luciferin and luciferase 
QuantiLum® recombinant firefly luciferase (FLuc) was purchased from Promega (USA) and 
prepared for 100 µg/ml aliquots. The storage buffer was prepared by following the 
manufacturer’s instructions and contained 25 mM Tris-Acetate (pH 7.4) (Sigma - Aldrich, St Louis, 
USA), 1 mM EDTA (Sigma - Aldrich), 1mM DTT (YA Kemia, Helsinki, Finland),  0.2 M ammonium 
sulfate (Riedel-de Haen, Seelze, Germany), 15 v/v % glycerol (BDH Prolabo, Helsinki, Finland) and 
30 % v/v ethylene glycol (Merck Worldwide, Espoo, Finland). Before the use the aliquots were 
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stored at -74 °C and melted at room temperature. A careful mixing of the aliquot with a pipette 
was required to remove the enzyme from the bottom of the tube. Poorly water soluble D-LH2 free 
acid (Sigma  Aldrich; purity ≥ 99 %) was diluted to 2 mg/ml 99.5 % ethanol stock (ACS Reagent, 
Thermo Fischer Scientific, Helsinki, Finland) and stored at +4 °C in the darkness to avoid 
racemization (Nakamura et al. 2005, Seliger et al. 1961). 
3.2.5. Release buffer 
A buffer solution for D-LH2 enzymatic release studies with FLuc was prepared according to 
manufacturer’s instructions with small modifications before the release experiment (Sigma - 
Aldrich, 2011). The prepared release buffer contained 4.4 mM magnesium sulfate heptahydrate 
(Sigma - Aldrich, Germany) and 1mM ATP (100 mM aqueous stock stored at -20 °C and melted at 
need) (Sigma - Aldrich, Germany) 1 x phosphate buffer saline (PBS) (Sigma-Aldrich, Germany) at 
pH 7.4. For preventing the aggregation between the nanoparticles bovine serum albumin fraction 
V (BSA) (VWR Prolabo, Celdenaaksebaan, France) was used achieving 0.01 w/v % concentration 
in the release buffer. 
3.2.6. Spectrometer and other instruments 
The washing of particles as well as loading and release tests were performed using sonication and 
centrifugation steps which were carried out with a Branson 2510E-MT Ultrasonicator instrument 
(Branson, Danbury, USA) and Eppendorf centrifuge 5415D (Eppendorf AG, Hamburg, Germany). 
Centrifugations were performed with a standard speed of 13,200 rounds per minutes always at 
room temperature. The samples were pipetted to a Lumitrac 200 96 fluorescent plate (Greiner-
Bio-One GmbH, Frickenhausen, Germany) for measuring the light emission. The fluorescent and 
luminescent measurements were performed with Fluoreskan/Luminoskan spectrophotometer 
(Thermo Fischer, Helsinki, Finland) at room temperature using Ascent Software Version 2.6. 
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3.2.7. The standard line of D-luciferin fluorescence 
The fluorescent of D-LH2 was measured with different concentrations of D-LH2 in order to find the 
linear concentration range of D-LH2. The standard line gave evidence which amount of D-luciferin 
should be used for the loading studies.  
The D-LH2 stock (2 mg/ml) (Sigma - Aldrich, USA) was diluted to 400 µg/ml of water. The stock 
solution, a 96-well plate, deionized water and a multichannel pipette was used for preparing the 
final 1 : 4 dilution series including concentrations from 0 to 250 µg/ml. Fluorescence was 
measured at room temperature. The excitation wavelength was 320 nm whilst the emission 
wavelength was kept as 538 nm. 
3.2.8. Comparison loading properties of mesoporous silicon particles 
In this study three types of particles (UnTHCPSi, TCPSi-NH2, WOPSi-NH2) were used in order to 
study the effect of the surface chemistry on the loading of D-LH2. The dilutions of D-LH2 were 
prepared by following the previously prepared D-LH2 fluorescence standard line.  
Before starting the study 50 µg of nanoparticles were washed and resuspensed to 2 mg/ml 
concentration using deionized water. The D-LH2 stock (2 mg/ml in water) was diluted to 
a concentration 200 µg/ml for the loading experiment. One 25 µl sample of the D-LH2 dilution was 
mixed with 25 µl of the nanoparticle suspension. The control sample was prepared identically 
replacing the particle suspension with deionized water. 
The loading was performed by incubating the samples at room temperature for one hour 
sonicating every 13 minute for 2 minutes. The procedure was finished with centrifugation for 
10 minutes. 25 µl of the supernatant was transferred to a 96-well plate for the fluorescence 
measurement. The loading degree and loading efficiency (mdrug loaded / (mdrug loaded + mun-loaded) × 
100 %) were determined. 
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3.2.9. Optimization the particle concentration for loading studies 
The TCPSi-NH2 particles were chosen for further studies because they showed the highest values 
of loading efficiency and loading degree. For this experiment a standard concentration of D-LH2 
was loaded to the nanoparticles with variable particle concentrations. The method enables to find 
the concentration for both the cargo and the nanoparticles which can be used for reaching a 
sufficient loading efficiency to simplify performing a release experiment. In this study 90 % loading 
efficiency was estimated to be sufficient for using the loading suspension directly for the release 
studies without an interfering background signal. 
At first, TCPSi-NH2 particles (680 µg) were washed three times and suspended to 3.6 mg/ml using 
deionized water. 17.5 µl of the D-LH2 stock (2 mg/ml) was diluted to 140 µg/ml of deionized water. 
The particle suspension was divided into five separate batches. D-LH2 and deionized water and 
particles were added in order to obtain 100 µl samples with 70 µg/ml of D-LH2 and one 400, 800, 
1400, 1600 or 1800 µg/ml of particles. The control sample was prepared identically but without 
nanoparticles. After that the loading was performed like previously. 20 µl of each sample was 
transferred to three parallel wells on a 96-well plate with 80 µl of water (1 : 5 dilution). The 
fluorescent was measured and the loading degree and loading efficiency were calculated for each 
sample as previously mentioned. 
3.2.10. Optimization the particle concentration for release studies 
Porous silicon nanoparticles are well-known to absorb light emitted from an external light source. 
The effect is likely to cause a loss of light signal in the very end of the kinetics measurements of 
luminescence reaction between FLuc and D-LH2. For this reason the nanoparticles were diluted 
with a constant concentration of D-LH2 in order to reduce light absorption caused by the particles. 
One of the particle concentrations was chosen by finding an intersection point in the dilution 
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series where the total light emission from the D-LH2-particle mixture is equal to the one of the 
control sample without any particles. 
At first, 213 µg of TCPSi-NH2 particles were washed three times with deionized water. The 
particles were diluted to 323 µl of the release buffer and mixed with 10 µl of D-LH2 (0.9 mg/ml in 
water). The prepared suspension was quickly sonicated and 100 µl samples were transferred 
immediately to three wells on the multiwell plate. The control sample was processed with the 
same method but without particles. 
Using a single-channel pipette and the release buffer the 1 : 2 dilution series for both new-loaded 
particle suspension and the control sample was prepared (50 µl/well). The reaction was initiated 
by adding 50 µl of the recombinant FLuc (20 µg/ml in the release buffer) to each well. Thus, each 
well contained a nanoparticle concentration of 0, 10, 20, 40, 80, 160 or 320 µg/ml and a D-LH2 
concentration of 0.4, 0.8, 1.6, 3, 7 or 14 µg/ml. Furthermore, each well contained a constant 
10 µg/ml concentration of FLuc. The luminescence was measured using the spectrophotometer. 
3.2.11. Study the drug release properties of mesoporous silicon nanoparticles using the 
bioluminescence of D-luciferin 
Based on the above-mentioned results of the loading studies the final study about release kinetics 
of the nanoparticles was performed. The release kinetics was studied with luminescent reaction 
initiated by the recombinant FLuc mixture.  
At first, 100 µg of TCPSi-NH2 nanoparticles were washed three times and resuspended to 3.2 
mg/ml using deionized water. The suspension was divided to two separated 25 µl samples serving 
as a loading sample and non-loading sample. 25 µl of D-LH2 (140 µg/ml in water) was added to 
the first sample and loading was performed like previously described. 
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For kinetics measurements, samples were transferred to three wells of a 96-well plate (Fig. 14). 
Six other wells were reserved for parallel samples (n = 3). To the first well, 5 µl of the loaded 
particles (8 µg) was transferred. To the second well, 2.5 µl of D-LH2 (350 ng) was added with 2.5 
µl of the un-loaded particles (8 µg). The loading of D-LH2 into the particles was prevented by 
keeping those drops apart on the opposite sides of the well until adding the FLuc recombinant 
mixture. To the last well, 2.5 µl of D-LH2 (350 ng) was added as a single drop with 2.5 µl of 
deionized water (control 2). This gives more data for comparison the results of loaded and un-
loaded particles. The plate was placed inside the luminometer. The lid of the instrument was 
opened for injecting 95 µl of the FLuc recombinant (950 ng) in the release buffer to each well. The 
volume of the release buffer was fixed for simulating the injection of the particles to a mouse. 
The luminescence was measured with one minute intervals. The measurement was continued at 
room temperature in the darkness for 18 hours. 
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Figure 14. A novel method for studying the release of D-luciferin (D-LH2) using mesoporous silicon 
nanoparticles. The samples were prepared using three wells of a 96-well plate. (a) At first D-LH2 loaded 
and un-loaded particles as well as water were added. (b) Drops of D-LH2 were added to the opposite site 
of un-loaded particles and the water drop. (c) The plate was transferred into the luminometer. (d) The lid 
was kept opened and a surplus of FLuc was injected to each well for starting the reaction. The lid was 
closed immediately and the light was measured with a luminometer in the darkness over the time. 
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3.3. Results 
3.3.1. The standard line of D-luciferin fluorescence 
According to the results, the linear concentration range of D-LH2 for the used spectrophotometer 
is 0 - 110 µg/ml. 
 
Figure 15. The linear relation of aqueous D-luciferin (D-LH2) concentration to the fluorescence at room 
temperature using Fluoroskan/Luminoskan spectrophotometer  instrument (Thermo Fischer, Helsinki, 
Finland) with an excitation wavelength of 320 nm and an emission wavelength of 538 nm. The error bars 
indicate standard deviations. (n = 3) 
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3.3.2. Comparison the loading properties of different porous silicon particles 
D-LH2 had the highest loading efficiency to the TCPSi-NH2 nanoparticles (68 %) (Fig. 16). TCPSi-
NH2 also reached to the best loading degree (12 % w/w) over the tested particles (UnTHCPSi 1 % 
w/w and WOPSi-NH2 4 % w/w). According to these results, TCPSi-NH2 is the most potent carrier 
for D-LH2. 
 
Figure 16. The loading efficiency of D-luciferin into three types of porous silicon nanoparticles in water 
after 1 hour incubation at room temperature (n = 1). The samples were sonicated every 13 minutes for 
2 minutes. The loading was carried out with 10 µg of D-luciferin and 50 µg of the nanoparticles in 50 µl of 
deionized water. The control sample contained 10 µg of D-luciferin in 50 µl of deionized water without 
nanoparticles expressing 100 %. 
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3.3.3. Optimization the particle concentration for loading studies 
The comparative loading study showed the TCPSi-NH2 particles to be the best alternative for the 
optimization steps. The aim of the optimization is to find the amount of TCPSi-NH2 particles which 
shows over 90 % loading efficiency for D-LH2 loading. 90 % loading efficiency was estimated to be 
sufficient for using the loading suspension directly for the release studies without an interfering 
background signal. In this study 93.9 % loading efficiency was achieved by using 140 µg of TCPSi-
NH2 nanoparticles, 7 µg of D-LH2 in 100 µl of water (the fourth data point in the figure 19). This 
means that 6.6 µg of D-LH2 was loaded. With 140 µg of TCPSi-NH2 a loading degree of 4.48 % w/w 
was achieved (table 1). 
 
Figure 19. Unbound D-luciferin in the loading supernatant after loading with five different concentrations 
of TCPSi-NH2. The loading was performed with 7 µg of D-luciferin in 100 µl of deionized water. The loading 
was carried out by incubating at room temperature for one hour. The control sample was 7 µg of D-
luciferin in 100 µl of deionized water expressing 100 %. The error bars indicate standard deviations. (n = 
3)  
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Table 1. Average loading degrees using 7 µg of D-luciferin with different concentrations of TCPSi-NH2 
nanoparticles in 100 µl of water. 
m (TCPSi-NH2) (µg)  40 80 140 160 180 
 % w/w 4,97 6,02 4,48 4,11 3,73 
 
3.3.4. Optimization of the particle concentration for release studies 
The D-LH2 loaded TCPSi-NH2 particles were diluted for the luminescence measurement in order 
to minimize the light absorption by TCPSi-NH2 during the enzymatic release studies. According to 
the results 2 µg of TCPSi-NH2 nanoparticles does not cause significant light absorption of 86 ng of 
D-LH2 in 100 µl of water. (Fig. 20) This means that the loading sample should be diluted to a 
concentration 20 µg/ml for measuring the luminescence. 
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Figure 20. Luminescence for un-loaded TCPSi-NH2 nanoparticles with D-luciferin and a particle free D-
luciferin solution in 100 µl of deionized water. The reaction was started with 950 µg of Luciferase. The 
error bars indicate standard deviations. (n = 3)  
3.3.5. Study the drug release properties of mesoporous silicon nanoparticles using D-luciferin 
The experimental parameters for the release study with the bioluminescent reaction between D-
LH2 and Fluc were chosen according to the following observations made above 
1. The linear concentration range of D-LH2 for the used fluorescence/luminescence instrument    
is 0 - 110 µg/ml. 
2. Among the three tested nanoparticles TCPSi-NH2 is the most suitable as carrier for D-LH2. 
3. 140 µg of TCPSi-NH2 nanoparticles are sufficient for achieving over 90 % loading efficiency 
when loaded with 7 µg of D-LH2 in 100 µl of water. With these amounts a loading degree of 
4.5 % w/w is reached. 
4. The D-LH2 loaded TCPSi-NH2 nanoparticles need to be diluted to a concentration 20 µg/ml for 
the enzymatic release study. 
For the release study the loading procedure was repeated. The average loading efficiency of D-
LH2 into TCPSi-NH2 was 76 % and the calculated loading degree was around 3.2 % w/w. The values 
differ from the previous loading results (Fig. 19; Table 1). The difference between the loading 
results may be explained with the differences between the sonication conditions which are 
explained with the fact that particles were sonicated by keeping the samples by hands on the 
water bath of the sonicator.  
In the current study the particle concentration was adjusted to a concentration 80 µg/ml in order 
to verify the results of the previous optimization study (3.4.5). Indeed, the kinetic data curve (Fig. 
21) shows a higher luminescence level for the sample without particles suggesting light 
absorption by the particles. 
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There are no significant differences between the luminescence values of the loaded nanoparticles 
and the non-loaded particles over the time reflecting the fact that almost all the D-LH2 is rapidly 
released out of the particles. The major difference between loaded and un-loaded nanoparticles 
is noticed within the first minute. In the beginning the luminescence stayed 1.8 times weaker with 
loaded nanoparticles than the one of the non-loaded D-LH2-TCPSi-NH2 mixture. Still, the initial 
burst effect of D-LH2 release is remarkable. After 10 minutes from the initiation the levels of 
luminescence of the both are equal till end of the measurements.  
  
Figure 21. A diagram of the luminecence either TCPSi-NH2 nanoparticles loaded by D-luciferin, non-loaded 
TCPSi-NH2 nanoparticles mixed with D-luciferin and free D-luciferin. For the measurement 5 µl of the 
loading suspension was used containing 350 ng of D-luciferin and 8 µg of TCPSi-NH2 nanoparticles. The 
first control contained 8 µg of TCPSi-NH2 nanoparticles with 350 ng of D-luciferin of un-loaded D-luciferin 
in 5 µl of water. The second control contained 350 ng of D-luciferin in 5 µl of water.  The reaction was 
started by adding 950 ng of luciferase in 95 µl of the release buffer. Here the used loading efficiency is 100 
% for clarity (the achieved loading efficiency was 76 %). Time-scale has also been reduced. The error bars 
indicate standard deviations. (n = 3) 
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3.4. Discussion 
3.4.1. Loading 
In the first part of the current study the loading of D-luciferin (D-LH2) into mesoporous silicon 
nanoparticles was studied. The studied particles were coded according to their surface 
chemistries as undecylenated thermal hydrocarbonized, amino carbonized and amino wet-
oxidized porous silicon nanoparticles (UnTHCPSi, TCPSi-NH2, WOPSi-NH2, respectively). The 
loading capacity of the particles was compared in order to find the best candidate for the 
following optimization step.  
The effect of the surface chemistry and pH. Like already stated, D-LH2 is well-known as poorly 
soluble drug-like compound. Both the TCPSi-NH2 and UnTHCPSi have hydrophobic carbonized and 
hydrocarbonized surfaces, respectively, so it is expected that the D-LH2 would have a strong 
interaction to both of the particles. UnTHCPSi loading was predicted to be more efficient because 
it is more hydrophobic than TCPSi-NH2. Surprisingly, the results of this study indicated that TCPSi-
NH2 had a higher loading efficiency (68 %) than UnTHCPSi (7 %) and also a better loading degree 
(12 % w/w, 1 % w/w, respectively). The difference in the loading capacities is explained with the 
pH of the loading solvent. In neutral water D-LH2 is mostly in the deprotonated form due to the 
small value of pKa (2.93) indicating a strong electrostatic attraction between the negatively 
charged thiazoline-carboxylic acid moiety of D-LH2 (Fig. 1.) and the positively charged TCPSi-NH2-
particles.  
Decreasing the pH would make D-LH2 far more acidic and also more hydrophobic, which increases 
the relevance of the hydrophobic forces to the loading like it was demonstrated with ibuprofen 
(Limnell et al. 2007, Salonen et al. 2005). More acidic environment would also decrease the charge 
of UnTHCPSi particles weakening the surrounding barrier enhancing the D-LH2 loading. However, 
avoiding pH manipulation is preferred due to the risk of aggregations within particles, which may 
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interfere the loading. In spite of the risk of particle aggregation, it would be interesting to study 
the effect of pH with freshly manufactured nanoparticles including also particles without surface 
modifications. Furthermore, the age of the used particle batches may have had an influence to 
the loading. To be precise, the UnTHCPSi batch was several months older than TCPSi-NH2 and may 
have been oxidized during the storage and the use in the previous studies.  
The low loading capacity of the WOPSi-NH2 contrary to the TCPSi-NH2 particles cannot be 
explained with the ζ-potential values. Instead of the surface groups the explanation can be found 
in different surface stabilization chemistries. The long storing time before the start of the 
experiment is also to have disturbed to the structure of WOPSi-NH2 particles having an influence 
in the loading results. The current loading experiment should be repeated using similarly aged 
particles while increasing the amount of parallel samples from one to three. 
The location of the loaded D-LH2. The current report does not show the exact location of the 
loaded D-LH2 on the particle surface. D-LH2 may be either accumulated to the pores or be partly 
adsorbed to the external surface. For sustained release it is more preferred to get D-LH2 to be 
loaded into the pores of PSi from which the escape is difficult. For an extended analysis of the 
success of loading some other analysis techniques are required. For instance N2 ad/desorption 
analysis and X-ray diffraction measurements are often run for many model drugs to study the 
portion and the physical state of a drug in porous silicon pores (Limnell et al. 2007, Salonen et al. 
2005, Wang et al. 2010). Nonetheless, the introduction of these methods to a study should be 
evaluated before the use because the most of them includes additional steps for sample 
preparation like solvent evaporation. Evaporation may form crystal and amorphous forms of D-
LH2 like it has observed to be happened with small pharmaceuticals (Salonen et al. 2005). Changes 
in a solid-state of D-LH2 during the evaporation may have unpredictable impacts on the release 
as well as on the bioluminescence activity.   
Effect of loading solution. Drug loading is also affected by the composition of the loading solution. 
Changing the solution may improve loading. Poorly soluble drugs which usually are not loaded 
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using water because it is hard to achieve sufficient drug concentrations. Since D-LH2 is a poorly 
water soluble molecule an optional loading solution might be a water-ethanol mixture. 
3.4.2. Release 
Another aim of this Master’s Thesis was to study the D-LH2 release from porous silicon 
nanoparticles. The release study was enzymatically performed with recombinant firefly luciferase 
(FLuc). D-LH2 is capable to be detected by measuring the visible light produced in the 
bioluminescence reaction catalyzed by FLuc. TCPSi-NH2 was chosen because of the best D-LH2 
loading previous loading results among the studied particles. 
The D-LH2 release kinetics. The original hypothesis was that the release of D-LH2 from TCPSi-NH2 
particles is sustained, which reduces the initial burst effect while prolonging the luminescence 
time. However, this study failed to achieve a constant release of D-LH2 which was demonstrated 
by comparing the light emission of non-loaded and loaded TCPSi-NH2 samples (Fig. 21). The high 
initial peak in the luminescence spectrum shows a rapid release of out of the particles. If the burst 
really occurs it may be a consequence of un-preferred loading to the external surface of the 
particles. It is reasonable to repeat the experiment by washing the loaded particles couple of 
times for external bound D-LH2. If the burst still occur in spite of washing, other techniques to 
achieve a controlled drug release should be tested. For example layer-by-layer self-assembly is 
worth applying (De Villiers et al. 2011, Yuan et al. 2010). 
The effect of the release medium. The suitability of the release medium should also be 
reconsidered. In this study the medium included 0.01 % w/v of bovin serum albumin (BSA). BSA 
was observed decreasing the aggregation between the particles during the release (data not 
shown) but the release medium requires optimization for D-LH2. The release medium would be 
exchanged another such as plasma in order to get better insight of the D-LH2 release after 
administrating to the body system. 
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The effect of the pore size. It is not known if the pore size was incorrect for sustained D-LH2 
release. Furthermore, too high pore size may allow the diffusion of luciferase into the particles. 
In that case the current release study shows the light which is produced inside the particles. This 
means there should not be significant restrictions for light coming outside from the pores. For 
example particles can absorb light in spite of whether the light comes from outside or inside the 
particles. The effect of the pore size should be studied using particles with variety pore sizes. 
Future aspects for controlled D-LH2 release. The original long-range outlook of this D-LH2 study 
is to simultaneously load luciferase-specific inhibitor compounds (FLICs) into porous silicon 
nanoparticles with different types of cell penetrating peptides (CPPs). Covalent conjugation of 
FLICs to the particles by a CPP-linkage would enable to study the escape of the particles from the 
endosomal/lysosomal compartment due to the strong conjugation chemistry which is barely 
unbroken by endosomal enzymes. (Poutiainen et al. Unpublished manuscript) Later on, the 
studies could be carried out by Fluc transfected cells and tissues which express constantly FLuc. 
FLuc transfection provides an opportunity to develop D-LH2 as an alternative imaging tool for in 
vivo nanoparticle research. 
3.5. Conclusion 
Mesoporous silicon nanoparticles are widely studied and a versatile tool for drug delivery 
applications. The aim of the study was to test the drug loading capacity and release kinetics of 
mesoporous silicon nanoparticles using D-luciferin as a drug like model molecule and use the 
luciferase catalyzed luminescence reaction for monitoring the kinetics of drug release from the 
particles. Thermal carbonized porous silicon amino particles (TCPSi-NH2) were found to have the 
highest D-LH2 loading capacity although the attraction seems not be enough for maintaining 
sustained release. Alternative methods to maintain the D-luciferin inside the mesoporous space 
are required. In spite of the undesired drug release from TCPSi-NH2 the method developed here 
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can be applied for comparing drug loading and release properties of other types of porous silicon 
nanoparticles. A release test can be carried out easily on a 96 well plate using the drop-by-drop 
methodology described in this report. In addition, interfering light absorption of porous silicon 
particles in the bioluminescence release test is also avoidable with the simple and quick dilution 
procedure. In summary, if the sustained or even eliminated D-LH2 release to any kind of porous 
silicon nanoparticles is achieved it would open the doors for developing a new bioluminescence 
based imaging method for studying drug delivery systems in cellular and even in vivo 
environment. 
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